Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 8/20 | 0.51 |
| ▸ | PDGFRB | P09619 | 7/20 | 0.51 |
| ▸ | KDR | P35968 | 6/20 | 0.51 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.47 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.47 |
| ▸ | TUBB3 | Q13509 | 3/20 | 0.45 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.45 |
| ▸ | TUBB | P07437 | 2/20 | 0.45 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.45 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.45 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.45 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.45 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.45 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.45 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.45 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.45 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 0.45 |
| ▸ | TUBB6 | Q9BUF5 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13413781 | 0.90 | EGFR (0.60) | EGFRPDGFRBKDRPDGFRAHDAC8 | |
| SCHEMBL3110955 | 0.85 | EGFR (0.69) | EGFRPDGFRBKDRPDGFRAHDAC8 | |
| SCHEMBL2256222 | 0.82 | KDR (0.68) | EGFRPDGFRBKDRPDGFRATUBB3 | |
| SCHEMBL3107580 | 0.82 | EGFR (0.47) | EGFRPDGFRBKDRPDGFRAHDAC8 | |
| SCHEMBL2255962 | 0.79 | EGFR (0.53) | EGFRPDGFRBKDRPDGFRAHDAC8 | |
| SCHEMBL13413782 | 0.78 | KDR (0.47) | EGFRPDGFRBKDRPDGFRATUBB3 | |
| SCHEMBL13413780 | 0.76 | KDR (0.50) | EGFRPDGFRBKDRPDGFRAHDAC8 | |
| SCHEMBL3113560 | 0.75 | EGFR (0.49) | EGFRPDGFRBKDRPDGFRAHDAC8 | |
| SCHEMBL3109780 | 0.75 | PDGFRB (0.43) | EGFRPDGFRBKDRPDGFRAHDAC8 | |
| SCHEMBL13413783 | 0.74 | KDR (0.61) | EGFRPDGFRBKDRPDGFRAHDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130029942-A1 | COMPOUNDS AND THERAPEUTICAL USES THEREOF | MYREXIS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-20130029942-A1 | COMPOUNDS AND THERAPEUTICAL USES THEREOF | MYREXIS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-8309562-B2 | Compounds and therapeutical use thereof | MYREXIS, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-8309562-B2 | Compounds and therapeutical use thereof | MYREXIS, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-20100069383-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | Myriad Pharmaceuticals, Incorporated (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100069383-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | Myriad Pharmaceuticals, Incorporated (US) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130029942-A1 | COMPOUNDS AND THERAPEUTICAL USES THEREOF | BAD, CASP3, BAX | EGFR 3147/4885PDGFRB 2783/4885KDR 3722/4885 |
| US-20100069383-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | EGFR 2648/4885PDGFRB 2627/4885KDR 3809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.